Related Experiment Video

Updated: Sep 26, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell

Randal W Berg1, Peter J Ferguson, Mark D Vincent

  • 1Cancer Research Laboratories, London Regional Cancer Centre, 790 Commissioners Road, London, Ontario, Canada N6A 4L6.

Cancer Gene Therapy
|April 8, 2003
PubMed

Insights

Combining multiple antisense oligodeoxynucleotides (ODNs) targeting thymidylate synthase (TS) mRNA can enhance cancer cell proliferation inhibition. However, this combination does not improve sensitivity to TS-directed chemotherapy drugs.

Area of Science:

  • Molecular Biology
  • Anticancer Drug Development

Background:

  • Thymidylate synthase (TS) is crucial for DNA synthesis and cell proliferation, making it a key target in antitumor chemotherapy.
  • Antisense oligodeoxynucleotides (ODNs) have been developed to downregulate TS mRNA and protein levels, inhibiting cancer cell growth.

Purpose of the Study:

  • To investigate the synergistic or antagonistic interactions of using multiple ODNs targeting distinct, noncontiguous regions of TS mRNA.
  • To determine if combined ODN treatment enhances the efficacy of TS-directed chemotherapeutic drugs.

Main Methods:

  • Designing and applying multiple antisense ODNs targeting different regions of the TS mRNA.
  • Evaluating the effects of individual and combined ODN treatments on TS mRNA abundance, protein levels, and cancer cell proliferation.
  • Assessing the impact of combined ODN treatment on cancer cell sensitivity to raltitrexed and 5-fluorodeoxyuridine.

Main Results:

  • Certain combinations of TS antisense ODNs demonstrated superior reduction in TS mRNA and inhibition of cell proliferation compared to individual ODNs.
  • Combined ODN treatment did not further augment the enhanced sensitivity to anti-TS chemotherapeutic drugs observed with individual ODNs.

Conclusions:

  • The combination of multiple antisense ODNs targeting distinct regions of TS mRNA can synergistically inhibit cancer cell proliferation.
  • The results suggest that TS mRNA or protein may have functions beyond thymidylate production that are targeted by antisense ODNs.
  • Using multiple antisense ODNs targeting different regions of the same mRNA is a promising strategy to enhance antisense therapy effectiveness.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...